For more than 10 years, Dow has been intimately involved in ophthalmic formulation development for various ocular diseases such as cataract, ocular hyphema, dry-eye, age-related macular degeneration, ...

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

The FDA had refused to approve the drug in December, but Outlook appealed the decision. ・The resubmission follows the agency's conclusion that no additional trials for Lytenava are required, as ...

When approved, ONS-5010/LYTENAVA™ will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust ...

Gerresheimer has developed a new dropper insert for ophthalmic formulations that it is showcasing at CPHI 2022 in Frankfurt, Germany. Gerresheimer announced on Oct. 26, 2022 that is has developed a ...

MISSION VIEJO, Calif.--(BUSINESS WIRE)--Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye ...

SINGAPORE and TAIPEI, April 30, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. NEW ORLEANS — An ophthalmic formulation of bevacizumab ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that ...

MISSION VIEJO, Calif.--(BUSINESS WIRE)--Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye ...

Drug major Cipla on Thursday said it has tied up with CSIR-Central Drug Research Institute to jointly develop a novel ophthalmic formulation for fungal keratitis. The collaboration aims to leverage ...